Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease
Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with sickle cell disease, aged 16